ArticleNature communications2023

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.

J Capdevila et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.